Literature DB >> 16179272

Angiogenic factors in atrial fibrillation: a possible role in thrombogenesis?

Bethan Freestone1, Aun Yeong Chong, Hoong Sern Lim, Andrew Blann, Gregory Y H Lip.   

Abstract

BACKGROUND: The precise pathophysiological processes underlying the prothrombotic or hypercoagulable state in atrial fibrillation (AF) remain uncertain. We hypothesized a relationship between abnormal endothelial damage/dysfunction, coagulation, and angiogenic factors, thereby contributing to increased thrombogenicity.
METHODS: Plasma levels of von Willebrand factor (vWF, an index of endothelial damage/dysfunction) and tissue factor (TF, an index of coagulation), as well as the angiogenic factors, vascular endothelial growth factor (VEGF), angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2), were measured by enzyme-linked immunosorbant assay (ELISA) in 59 chronic AF patients. Data were compared to 40 age- and sex-matched healthy controls in sinus rhythm.
RESULTS: Plasma vWF, VEGF and Ang-2 were significantly higher in AF patients compared to healthy controls (P=0.005, P=0.0055 and P<0.0001 respectively) but there were no significant differences in plasma Ang-1 or TF levels between the two groups (P=0.925 and P=0.121 respectively). Significant correlations were found between VEGF and vWF levels (Spearman, r=0.262, P=0.011) and between VEGF and Ang-2 (r=0.333, P=0.001).
CONCLUSIONS: Raised VEGF in association with Ang-2 and vWF may reflect a link between abnormal endothelial damage/dysfunction and angiogenic factors. These may act together to alter TF expression and endothelial integrity, thereby contributing to the prothrombotic state in AF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16179272     DOI: 10.1080/07853890510037392

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  12 in total

1.  Elevated Angiopoietin-2 Level in Patients With Continuous-Flow Left Ventricular Assist Devices Leads to Altered Angiogenesis and Is Associated With Higher Nonsurgical Bleeding.

Authors:  Corey E Tabit; Phetcharat Chen; Gene H Kim; Savitri E Fedson; Gabriel Sayer; Mitchell J Coplan; Valluvan Jeevanandam; Nir Uriel; James K Liao
Journal:  Circulation       Date:  2016-06-28       Impact factor: 29.690

Review 2.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  Heart Rhythm       Date:  2016-06-10       Impact factor: 6.343

Review 3.  Atrial fibrillation: the role of hypoxia-inducible factor-1-regulated cytokines.

Authors:  Savalan Babapoor-Farrokhran; Deanna Gill; Jafar Alzubi; Sumeet K Mainigi
Journal:  Mol Cell Biochem       Date:  2021-02-11       Impact factor: 3.396

Review 4.  Angiopoietins, abdominal aortic aneurysm and atherosclerosis.

Authors:  Alexandra F Trollope; Jonathan Golledge
Journal:  Atherosclerosis       Date:  2010-08-19       Impact factor: 5.162

5.  Blood-Based Biomarkers to Search for Atrial Fibrillation in High-Risk Asymptomatic Individuals and Cryptogenic Stroke Patients.

Authors:  Elena Palà; Alejandro Bustamante; Jorge Pagola; Jesus Juega; Jaume Francisco-Pascual; Anna Penalba; Maite Rodriguez; Mercedes De Lera Alfonso; Juan F Arenillas; Juan Antonio Cabezas; Soledad Pérez-Sánchez; Francisco Moniche; Reyes de Torres; Teresa González-Alujas; Josep Lluís Clúa-Espuny; Juan Ballesta-Ors; Domingo Ribas; Juan Acosta; Alonso Pedrote; Felipe Gonzalez-Loyola; Delicia Gentile Lorente; Miguel Ángel Muñoz; Carlos A Molina; Joan Montaner
Journal:  Front Cardiovasc Med       Date:  2022-07-04

Review 6.  Evaluating the Atrial Myopathy Underlying Atrial Fibrillation: Identifying the Arrhythmogenic and Thrombogenic Substrate.

Authors:  Jeffrey J Goldberger; Rishi Arora; David Green; Philip Greenland; Daniel C Lee; Donald M Lloyd-Jones; Michael Markl; Jason Ng; Sanjiv J Shah
Journal:  Circulation       Date:  2015-07-28       Impact factor: 29.690

7.  Does an imbalance in circulating vascular endothelial growth factors (VEGFs) cause atrial fibrillation in patients with valvular heart disease?

Authors:  Keke Wang; Yanyan Liu; Suiqing Huang; Huayang Li; Jian Hou; Jiaxing Huang; Jiantao Chen; Kangni Feng; Mengya Liang; Guangxian Chen; Zhongkai Wu
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

8.  Tissue factor, blood coagulation, and beyond: an overview.

Authors:  Arthur J Chu
Journal:  Int J Inflam       Date:  2011-09-20

9.  EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  J Arrhythm       Date:  2016-07-11

10.  Identification of microRNAs and genes as biomarkers of atrial fibrillation using a bioinformatics approach.

Authors:  Yingyuan Li; Wulin Tan; Fang Ye; Faling Xue; Shaowei Gao; Wenqi Huang; Zhongxing Wang
Journal:  J Int Med Res       Date:  2019-06-20       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.